- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 295
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Turner Syndrome, Idiopathic Short Stature
- Interventions
- somatropin (rDNA)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 7 Years to 14 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Early Breast Cancer
- Interventions
- Ribociclib, Endocrine Therapy (ET)
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 5,101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 68 more
- Conditions
- Growth Hormone Insensitivity Syndrome (GHIS), Laron Syndrome
- Interventions
- rhIGF-I/rhIGFBP-3
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 2 Years to 18 Years
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Adult Growth Hormone Deficiency, Mild Traumatic Brain Injury
- Interventions
- Somatropin, Placebo
- Drug · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 13 more
- Conditions
- Metabolic Syndrome
- Interventions
- Norditropin
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
- Interventions
- Zovegalisib, Capivasertib, Fulvestrant
- Drug
- Lead sponsor
- Relay Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 52
- States / cities
- Gilbert, Arizona • Beverly Hills, California • Duarte, California + 42 more
- Conditions
- Advanced Nonsmall Cell Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Advanced or Metastatic Breast Cancer
- Interventions
- PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus, Exemestane
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 9
- States / cities
- Irvine, California • Los Angeles, California • Newport Beach, California + 3 more
- Conditions
- Breast Cancer
- Interventions
- Abemaciclib, Letrozole
- Drug
- Lead sponsor
- Mridula George, MD
- Other
- Eligibility
- 60 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 4
- States / cities
- Belleville, New Jersey • Livingston, New Jersey • New Brunswick, New Jersey + 1 more
- Conditions
- Abdominal Obesity, Growth Hormone Deficiency
- Interventions
- Growth hormone releasing hormone (GHRH) 1-44, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Phelan-McDermid Syndrome, Autism Spectrum Disorder (ASD)
- Interventions
- Growth Hormone, Saline
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone), Endocrine System Diseases, Hormones, Pituitary Diseases
- Interventions
- Once weekly subcutaneous injection of TransCon hGH, Once daily subcutaneous injection of Genotropin
- Drug
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/S
- Industry
- Eligibility
- 3 Years to 12 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 13 more
- Conditions
- Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma
- Interventions
- Fulvestrant, Repotrectinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
- Interventions
- Lonapegsomatropin
- Drug
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/S
- Industry
- Eligibility
- 23 Years to 81 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Torrance, California • Chicago, Illinois + 12 more
- Conditions
- Crohn's Disease
- Interventions
- Growth Hormone, Nutraceutical Combination, Exclusion Diet, Placebo Growth Hormone
- Drug · Dietary Supplement · Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 10 Years to 17 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer
- Interventions
- filgrastim, carmustine, cisplatin, melphalan, vinorelbine tartrate, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 70 Years · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Growth Hormone Deficiency
- Interventions
- LUM-201
- Drug
- Lead sponsor
- Lumos Pharma
- Industry
- Eligibility
- 3 Years to 13 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 7
- States / cities
- San Diego, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 4 more
- Conditions
- Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent
- Interventions
- Liothyronine (L-T3), Bevacizumab, Irinotecan, Temozolomide (TMZ)
- Drug
- Lead sponsor
- Sabine Mueller, MD, PhD
- Other
- Eligibility
- 1 Year to 25 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 2
- States / cities
- San Francisco, California • Washington D.C., District of Columbia
- Conditions
- Pediatric Growth Hormone Deficiency
- Interventions
- Experimental: VRS-317
- Drug
- Lead sponsor
- Versartis Inc.
- Industry
- Eligibility
- 3 Years to 11 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 23
- States / cities
- Clovis, California • Los Angeles, California • San Diego, California + 20 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Palbociclib, Fulvestrant, Avelumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 22
- States / cities
- Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 18 more
- Conditions
- Advanced Solid Tumor
- Interventions
- BNT326, Pumitamig, Itraconazole, Paroxetine
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more
- Conditions
- Prostate Cancer, Pain
- Interventions
- Azacitidine, Docetaxel, Prednisone, GADD45α methylation and expression analysis, Pegfilgrastim, Filgrastim
- Drug · Genetic
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Primary Insulin-like Growth Factor-1 Deficiency
- Interventions
- mecasermin [rDNA origin] injection
- Biological
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Basking Ridge, New Jersey